Breadcrumb Home Media centre Media releases Media Releases Quick Explore In the news Featured Stories Can - Helper: India’s first toll-free emotional support helpline for cancer patients and their families Cipla and Stempeutics collaborate for launch of Stempeucel®, first ‘Made in India’ Cell Therapy to treat Critical Limb Ischemia (CLI) Cipla receives regulatory approval for launch of Ciplenza (Favipiravir 200 mg) in India to treat mild to moderate COVID-19 Cipla receives final USFDA approval for generic version of Shire’s Firazyr® (Icatibant Injectable Pre-Filled Syringe 30mg/3mL) Year 20202019201820172016201520142013201220112010 Search News Apply Media Releases 2020 Cipla launches 'Covi-G' for COVID-19 rapid antibody detection Cipla launches ‘ELIFast’ (IgG ELISA test) for COVID-19 antibody detection Cipla launches Nintib (Nintedanib capsules 100 mg, 150 mg) to treat Idiopathic Pulmonary Fibrosis, in continuation of its fight against rare lung diseases Cipla receives final approval for generic version of Biogen IDEC Inc.’s Tecfidera® (Dimethyl Fumarate DR Capsules 120mg, 240mg and 120mg/240mg Starter Pack) Can - Helper: India’s first toll-free emotional support helpline for cancer patients and their families Cipla and Stempeutics collaborate for launch of Stempeucel®, first ‘Made in India’ Cell Therapy to treat Critical Limb Ischemia (CLI) Cipla receives regulatory approval for launch of Ciplenza (Favipiravir 200 mg) in India to treat mild to moderate COVID-19 Cipla receives final USFDA approval for generic version of Shire’s Firazyr® (Icatibant Injectable Pre-Filled Syringe 30mg/3mL) Cipla and Boehringer Ingelheim forge partnership to co-market three oral anti-diabetic drugs Cipla launches Cipremi (remdesivir lyophilised powder for injection 100 mg), the only U.S. FDA approved Emergency Use Authorisation (EUA) treatment for patients with severe COVID-19 disease Cipla expands partnership with Roche Pharma India to further improve access to key oncology medicines Cipla receives final approval for generic version of Migranal® (Dihydroergotamine Mesylate Nasal Spray 4mg/mL) with a Competitive Generic Therapy Designation Cipla files ANDA for generic version of GSK’s Advair Diskus® Cipla enters into a licensing agreement With Gilead to expand access to COVID-19 treatment Cipla stands strong with India in the battle against COVID-19 Cipla receives final approval for generic version of Proventil® HFA Inhalation Aerosol (Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation) Cipla announces successful completion of Phase-3 clinical study for generic version of GSK’s Advair Diskus® Cipla receives final approval for generic version of AstraZeneca Pharmaceutical’s Nexium® (Esomeprazole for Oral Suspension 10mg, 20mg and 40mg) Cipla Expands Women’s Health Portfolio through Acquisition of 4 Key Brands from Wanbury Cipla Foundation sets up a dedicated state-of-the-art chemistry laboratory at IISER Pune
